BRAF Mutation: 14 Real Stories

Stage IVB lung adenocarcinoma with severe immune-related complications

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 TPS 20%; BRAF mutation

Metastatic Site: left supraclavicular fossa, left axilla, right hilum,…

The patient had an initial partial response to ipilimumab/nivolumab but developed severe immune-related pneumonitis, thrombocytopenia, and aplastic anemia. Cytopenias recovered with eltrombopag, but lung cancer later relapsed with carcinomatous meningitis, and he died 20 months after diagnosis.

PubMed CentralRead more →

BRAF-mutant stage IV lung adenocarcinoma complicated by immunotherapy-induced diabetes

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: BRAF mutation; GADA-positive during immune-related diabetes evaluation

Metastatic Site: left lower lung, pleural

The patient had Stage IV BRAF V600E-mutant lung adenocarcinoma treated with targeted therapy and later tislelizumab. Immunotherapy was suspended after hypoadrenocorticism and diabetic ketosis; she required ongoing insulin therapy, with persistently low C-peptide at 6-month follow-up.

PubMed CentralRead more →

Stage IV BRAF Colorectal Adenocarcinoma: Pio's Patient Story

Patient Info: Pio, Male, 50s | Stage IV

Biomarkers: BRAF V600 mutation

Metastatic Site: peritoneum; liver; left lung nodules

After initial chemotherapy produced mixed results and May imaging showed growth, BRAF/EGFR-directed treatment led to a marked improvement on July scans.

The Patient StoryRead more →

Stage III dMMR transverse colon cancer: colectomy and adjuvant FOLFOX with no recurrence on CT

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Loss of MLH1 and PMS2; BRAF mutation; MMR-deficient colorectal cancer

After colectomy and initiation of planned adjuvant FOLFOX, surveillance abdominal CT showed no recurrence or metastasis.

PubMed CentralRead more →

Stage IVA EGFR-mutant lung adenocarcinoma: response to triple targeted therapy and surgery

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR exon 19 deletion; acquired BRAF V600E mutation in progressive lesion while EGFR exon 19 deletion persisted

Metastatic Site: pleura, pulmonary metastases; mediastinal and left…

As of May 2025, she continued osimertinib, dabrafenib, and trametinib after segmentectomy/lymphadenectomy, with 1% viable residual tumor in resected lung lesions, complete nodal pathologic response, and no disease progression.

PubMed CentralRead more →

Stage IV BRAF Colorectal Cancer: Jackson's Patient Story

Patient Info: Jackson, Male, Under 40 | Stage IV

Biomarkers: BRAF mutation

Metastatic Site: Liver; peritoneal wall

Jackson had Stage IV BRAF-mutated colon cancer with extensive liver disease and later confirmed peritoneal-wall tumors. His treatment response was strong, with about 90% of liver disease estimated gone, but he remained on active treatment with possible future HIPEC evaluation. As of September 2025, he was responding well but not cancer-free.

The Patient StoryRead more →

Stage IV BRAF Colorectal Cancer: Jennifer's Survivor Story

Patient Info: Jennifer, Female, Under 40 | Stage IV

Biomarkers: BRAF alteration reported

Metastatic Site: lungs

Jennifer described herself as about 2 years out from being cured after lung resections and additional chemotherapy for metastatic colon cancer.

The Patient StoryRead more →

Sophie: Stage IV Colorectal Cancer

Patient Info: Sophie, Female | Stage IV

Biomarkers: BRAF mutation; MSI

Metastatic Site: Liver; lymph nodes; other torso lesions

As of August 2024, Sophie had been declared cancer-free after Stage IV BRAF-mutated/MSI bowel cancer responded to nivolumab/ipilimumab-based immunotherapy, with PET imaging and liver surgery biopsy showing no cancerous cells.

The Patient StoryRead more →

Stage IV BRAF Colorectal Cancer: Sophie's Survivor Story

Patient Info: Sophie, Female | Stage IV

Biomarkers: BRAF-mutated; MSI / microsatellite instability

Metastatic Site: liver; lymph nodes including neck

As of June 2024, Sophie had been off treatment for nearly 3 years and described herself as currently cancer-free after surgery, chemotherapy, immunotherapy, and liver surgery showing no cancer cells.

The Patient StoryRead more →

Lung cancer treated with targeted therapy: rare blood vessel inflammation as a side effect

Patient Info: Anonymized, Female | Stage IV

Biomarkers: BRAF mutation

Metastatic Site: pleura

She initially achieved a complete response. After vasculitis treatment, targeted therapy continued and a partial lung-cancer response remained maintained without vasculitis recurrence.

PubMed CentralRead more →

Stage IV BRAF Colorectal Cancer: Loralee's Patient Story

Patient Info: Loralee Lovell, Female | Stage IV

Biomarkers: BRAF mutation; microsatellite stable

Metastatic Site: liver|lungs|lymph nodes|peritoneal lining

Loralee continued treatment for metastatic colon cancer for several years and died on May 26, 2026.

Fight Colorectal CancerRead more →

MET-mutated lung cancer: testing savolitinib before surgery

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: MET exon 14 skipping, TP53 and BRAF mutations; PD-L1 expression 5%

Metastatic Site: pleura; mediastinal lymph node

Savolitinib produced a partial radiological response, but surgery confirmed persistent pleural and mediastinal nodal metastases with ypStage IVA disease. He recovered and continued adjuvant savolitinib.

PubMed CentralRead more →

Malignant Struma Ovarii Managed With Surgery and Long-Term Surveillance

Patient Info: Anonymized, Female

Biomarkers: BRAF mutation negative

She remained asymptomatic with thyroid-stimulating hormone at the treatment goal and entered long-term thyroglobulin surveillance.

PubMed CentralRead more →

Metastatic Colon Cancer With KRAS, NRAS, and BRAF Mutations

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS exon 3 ; NRAS exon 2 ; BRAF exon 10 ; PIK3CA exon 2 .

Metastatic Site: liver

The liver metastases progressed despite FOLFOX and bevacizumab, and he died within one year of the initial diagnosis.

PubMed CentralRead more →